Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage clinical study, a boost for the ...

The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during ...

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

Bayer has reported encouraging topline findings from its global phase 3 OCEANIC-STROKE study, evaluating the investigational ...

The positive result in OCEANIC-STROKE means that asundexian can potentially now sit alongside prostate cancer therapy Nubeqa ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.

Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...